+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Insulin Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5939718
The insulin drugs market size has grown rapidly in recent years. It will grow from $31.09 billion in 2023 to $34.6 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The expansion observed in the historical period can be attributed to factors such as the increase in diabetes prevalence, growth in emerging markets, an increased geriatric population, and the growth in the use of insulin analogues.

The insulin drugs market size is expected to see rapid growth in the next few years. It will grow to $51.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The anticipated growth in the forecast period can be attributed to factors such as the increase in disease burden, government initiatives, and a rise in research and development (R&D) activities along with collaborations. Significant trends expected in the forecast period include the launch of new products to enhance product offerings, the expansion of product portfolios and businesses through mergers and acquisitions, the adoption of strategic partnerships to promote product offerings, increased investments in research and development for the development of new insulin delivery methods, and the investment in advanced solutions to reduce R&D costs and accelerate development timelines.

The increasing prevalence of diabetes, driven by changing lifestyles marked by long working hours, reduced physical activity, and unhealthy eating habits, is anticipated to boost the demand for diabetes drugs in the forecast period. Sedentary lifestyles have been linked to a higher incidence of diabetes, and individuals suffering from obesity face up to an 80-fold increased risk of developing type 2 diabetes. Projections from the World Health Organization (WHO) indicate a concerning trend, with an expected 74% of men and 64% of women in the UK being overweight by 2030. This surge in diabetes cases is likely to propel the diabetes therapies market.

The insulin drugs market is poised for growth due to the rising prevalence of obesity, a known risk factor for diabetes. Obesity, characterized by excess body fat adversely affecting health, is closely linked to diabetes development. Insulin drugs, used in the context of obesity, can contribute to weight gain, exacerbating the obesity issue. In England, for instance, projections from the Government Digital Service indicate a 25.2% increase in obesity among individuals aged 18 and older in the period 2021–2022. The escalating rates of obesity are a key driver for the growth of the insulin drugs market.

A discernible trend in the insulin market is the increasing number of mergers and acquisitions focused on developing new formulations. Companies are actively investing in innovative medicines for diabetes treatment. Researchers at Lund University Diabetes Centre utilized CRISPR, a genome modification tool, to turn off genes responsible for diabetes, resulting in increased insulin production and decreased beta cell death. Novo Nordisk has developed a diabetes pill based on glucagon-such as peptide-1 (GLP-1s) that stimulates insulin production, anticipating significant annual sales.

Major companies in the insulin drugs market are emphasizing product innovation, exemplified by the introduction of the triple fixed-dose combination (FDC) of teneligliptin with pioglitazone and metformin. Glenmark Pharmaceuticals Limited, an Indian pharmaceutical company, launched Zita-PioMet, a triple FDC for treating type 2 diabetes and high insulin resistance. This innovation aims to improve glycemic control in adults with uncontrolled diabetes despite other treatments.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Protomer Technologies Inc. for $1 billion. This acquisition enhances Lilly's capabilities in insulin therapy advancements, particularly in developing glucose-sensing insulin. Protomer Technologies, a pre-clinical stage biotechnology company, specializes in research and technology development for metabolic disorders, aligning with Lilly's commitment to improving the lives of diabetes patients.

Major companies operating in the insulin drugs market report are Novo Nordisk, Sanofi S.A., Eli Lilly And Company, Biocon Ltd., and Gan & Lee Pharmaceuticals, Bioton, Wockhardt Ltd., Julphar, Tonghua Dongbao Pharmaceutical, AstraZeneca, Mehar healthcare, GE Healthcare, Philips Healthcare India, Shandong WeiGao Group Medical Polymer Company Limited, Yuwell Medical Equipment & Supply Co, Terumo, NIPRO, Olympus Medical Systems, Hitachi Medico, Nihon Kohden, Fukuda Denshi, Emperra GmbH E-Health Technologies, DIABNEXT™, Berlin-Chemie AG, Ypsomed Holding AG, Patients Pending Ltd., Dexcom, Johnson and Johnson, Medtronic, Abbott Laboratories, Acon Laboratories, Ypsomed AG, Tandem Diabetes Care, Inc., Becton, Dickinson, Insulet Corporation, AJA Pharma, SEDICO Pharmaceutical Company, Pfizer.

North America was the largest region in the insulin drugs market in 2023. The Middle East is expected to be the largest growing region in the global insulin drugs market share during the forecast period. The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insulin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary product types of insulin drugs include basal or long-acting insulins, bolus or fast-acting insulins, pre-mixed insulins, and intermediate and short-acting insulins. Basal or long-acting insulins are utilized in diabetes management to provide a slow, steady release of insulin throughout the day and night. Insulin source types include insulin analogs and human insulin, while drugs are categorized into branded and generic drugs, distributed through hospital pharmacies, retail pharmacies, and online platforms. The various applications of insulin drugs encompass type II diabetes, type I diabetes, and gestational diabetes.

The insulin drugs market research report is one of a series of new reports that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry. This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin drugs market consists of sales of rapid-acting insulin, short-acting insulin, and mixed insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. Insulin Drugs Market Characteristics3. Insulin Drugs Market Trends and Strategies
4. Insulin Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Insulin Drugs Market Size and Growth
5.1. Global Insulin Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Insulin Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Insulin Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Insulin Drugs Market Segmentation
6.1. Global Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Basal Or Long-Acting Insulins
  • Bolus Or Fast-Acting Insulins
  • Pre-Mixed
  • Intermediate and Short Acting Insulins
6.2. Global Insulin Drugs Market, Segmentation by Source Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Insulin Analogs
  • Human Insulin
6.3. Global Insulin Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded Drugs
  • Generic Drugs
6.4. Global Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
6.5. Global Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
7. Insulin Drugs Market Regional and Country Analysis
7.1. Global Insulin Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Insulin Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Insulin Drugs Market
8.1. Asia-Pacific Insulin Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Insulin Drugs Market
9.1. China Insulin Drugs Market Overview
9.2. China Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Insulin Drugs Market
10.1. India Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Insulin Drugs Market
11.1. Japan Insulin Drugs Market Overview
11.2. Japan Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Insulin Drugs Market
12.1. Australia Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Insulin Drugs Market
13.1. Indonesia Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Insulin Drugs Market
14.1. South Korea Insulin Drugs Market Overview
14.2. South Korea Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Insulin Drugs Market
15.1. Western Europe Insulin Drugs Market Overview
15.2. Western Europe Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Insulin Drugs Market
16.1. UK Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Insulin Drugs Market
17.1. Germany Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Insulin Drugs Market
18.1. France Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Insulin Drugs Market
19.1. Italy Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Insulin Drugs Market
20.1. Spain Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Insulin Drugs Market
21.1. Eastern Europe Insulin Drugs Market Overview
21.2. Eastern Europe Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Insulin Drugs Market
22.1. Russia Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Insulin Drugs Market
23.1. North America Insulin Drugs Market Overview
23.2. North America Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Insulin Drugs Market
24.1. USA Insulin Drugs Market Overview
24.2. USA Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Insulin Drugs Market
25.1. Canada Insulin Drugs Market Overview
25.2. Canada Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Insulin Drugs Market
26.1. South America Insulin Drugs Market Overview
26.2. South America Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Insulin Drugs Market
27.1. Brazil Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Insulin Drugs Market
28.1. Middle East Insulin Drugs Market Overview
28.2. Middle East Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Insulin Drugs Market
29.1. Africa Insulin Drugs Market Overview
29.2. Africa Insulin Drugs Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Insulin Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Insulin Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Insulin Drugs Market Competitive Landscape and Company Profiles
30.1. Insulin Drugs Market Competitive Landscape
30.2. Insulin Drugs Market Company Profiles
30.2.1. Novo Nordisk
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Sanofi S.A.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Eli Lilly and Company
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Biocon Ltd
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. and Gan & Lee Pharmaceuticals
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Insulin Drugs Market Other Major and Innovative Companies
31.1. Bioton
31.2. Wockhardt Ltd
31.3. Julphar
31.4. Tonghua Dongbao Pharmaceutical
31.5. AstraZeneca
31.6. Mehar healthcare
31.7. GE Healthcare
31.8. Philips Healthcare India
31.9. Shandong WeiGao Group Medical Polymer Company Limited
31.10. Yuwell Medical Equipment & Supply Co
31.11. Terumo
31.12. NIPRO
31.13. Olympus Medical Systems
31.14. Hitachi Medico
31.15. Nihon Kohden
32. Global Insulin Drugs Market Competitive Benchmarking33. Global Insulin Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Insulin Drugs Market
35. Insulin Drugs Market Future Outlook and Potential Analysis
35.1 Insulin Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Insulin Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Insulin Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Insulin Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insulin drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for insulin drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Product Type: Basal Or Long-Acting Insulins; Bolus Or Fast-Acting Insulins; Pre-Mixed; and Intermediate and Short Acting Insulins
2) By Source Type: Insulin Analogs; and Human Insulin
4) By Drug Classification: Branded Drugs, and Generic Drugs
3) By Application: Type 2 Diabetes; Type 1 Diabetes; and Gestational Diabetes
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; and Online

Key Companies Mentioned: Novo Nordisk; Sanofi S.A.; Eli Lilly and Company; Biocon Ltd; and Gan & Lee Pharmaceuticals

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novo Nordisk
  • Sanofi S.A.
  • Eli Lilly And Company
  • Biocon Ltd
  • and Gan & Lee Pharmaceuticals
  • Bioton
  • Wockhardt Ltd
  • Julphar
  • Tonghua Dongbao Pharmaceutical
  • AstraZeneca
  • Mehar healthcare
  • GE Healthcare
  • Philips Healthcare India
  • Shandong WeiGao Group Medical Polymer Company Limited
  • Yuwell Medical Equipment & Supply Co
  • Terumo
  • NIPRO
  • Olympus Medical Systems
  • Hitachi Medico
  • Nihon Kohden
  • Fukuda Denshi
  • Emperra GmbH E-Health Technologies
  • DIABNEXT™
  • Berlin-Chemie AG
  • Ypsomed Holding AG
  • Patients Pending Ltd
  • Dexcom
  • Johnson and Johnson
  • Medtronic
  • Abbott Laboratories
  • Acon Laboratories
  • Ypsomed AG
  • Tandem Diabetes Care, Inc.
  • Becton
  • Dickinson
  • Insulet Corporation
  • AJA Pharma
  • SEDICO Pharmaceutical Company
  • Pfizer

Methodology

Loading
LOADING...